# What's new in Parkinson's disease research

## Randomized Controlled Trials

**Acupuncture versus sham acupuncture in the treatment of insomnia for patients with Parkinson's disease: a randomized controlled clinical trial.**  
This randomized controlled trial found that acupuncture significantly improved sleep quality in Parkinson’s patients with insomnia compared to sham acupuncture, with benefits maintained over 16 weeks, supporting acupuncture as a safe and effective treatment option for PD-related insomnia.  
*Citation: Acupuncture versus sham acupuncture in the treatment of insomnia for patients with Parkinson's disease: a randomized controlled clinical trial, BMC complementary medicine and therapies, 07/19/2025, PMID: [40684211](https://www.ncbi.nlm.nih.gov/pubmed/40684211)*

---

## Observational Studies (cohort studies, case-control studies, cross-sectional studies)

**Detecting delirium in Parkinson's disease: an evaluation of diagnostic accuracy of bedside tools.**  
This observational study evaluated standard bedside tools for detecting delirium in hospitalized Parkinson’s patients, finding that bedside tests, especially 4AT, are sensitive and practical, but caution that underlying cognitive impairment can affect diagnostic accuracy.  
*Citation: Detecting delirium in Parkinson's disease: an evaluation of diagnostic accuracy of bedside tools, Age and ageing, 07/01/2025, PMID: [40684269](https://www.ncbi.nlm.nih.gov/pubmed/40684269)*

**Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome.**  
Lower baseline language scores predicted worse disease progression, cognitive decline, and increased neurofilament-light chain in PSP-Richardson syndrome, suggesting that language assessment may improve prognosis and trial stratification.  
*Citation: Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome, Alzheimer's & dementia, 07/01/2025, PMID: [40684253](https://www.ncbi.nlm.nih.gov/pubmed/40684253)*

**The correlation between RLS and motor or other non-motor symptoms of PD patients: an observational study.**  
No abstract available for summarization.  
*Citation: The correlation between RLS and motor or other non-motor symptoms of PD patients: an observational study, BMC neurology, 07/19/2025, PMID: [40684087](https://www.ncbi.nlm.nih.gov/pubmed/40684087)*

**Unlocking the daily impact of Parkinson's challenges through a comprehensive assessment using the ChulaPD ADL questionnaire.**  
The ChulaPD ADL questionnaire, validated in Parkinson’s patients, is a reliable and effective tool for assessing daily functional limitations and disease progression.  
*Citation: Unlocking the daily impact of Parkinson's challenges through a comprehensive assessment using the ChulaPD ADL questionnaire, Scientific reports, 07/19/2025, PMID: [40683930](https://www.ncbi.nlm.nih.gov/pubmed/40683930)*

**Longitudinal association between plasma epidermal growth factor and the progression of anxiety and depressive symptoms in Parkinson's disease.**  
Higher baseline plasma epidermal growth factor (EGF) levels in drug-naïve Parkinson’s patients were associated with slower progression of anxiety and depressive symptoms, supporting EGF as a promising monitoring biomarker and therapeutic target.  
*Citation: Longitudinal association between plasma epidermal growth factor and the progression of anxiety and depressive symptoms in Parkinson's disease, Psychoneuroendocrinology, 07/14/2025, PMID: [40683110](https://www.ncbi.nlm.nih.gov/pubmed/40683110)*

**Neuropsychiatric fluctuations in Parkinson's disease: A French multicenter study of the NFS psychometric properties.**  
The Neuropsychiatric Fluctuation Scale (NFS) is validated as a reliable, sensitive, and specific tool for assessing neuropsychiatric fluctuations in Parkinson’s patients in clinical settings.  
*Citation: Neuropsychiatric fluctuations in Parkinson's disease: A French multicenter study of the NFS psychometric properties, Parkinsonism & related disorders, 07/11/2025, PMID: [40683099](https://www.ncbi.nlm.nih.gov/pubmed/40683099)*

**The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementia.**  
Blood-based biomarkers, particularly NfL, GFAP, and p-tau181, improve the differential diagnosis and monitoring of Parkinson’s, Alzheimer’s, and frontotemporal dementia, though specificity still requires refinement through integrated biomarker panels.  
*Citation: The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementia, Journal of the neurological sciences, 07/11/2025, PMID: [40682931](https://www.ncbi.nlm.nih.gov/pubmed/40682931)*

**Utilization of home-based traditional Chinese medicine in a homebound population under the integrated home-based medical care program in Taiwan.**  
Only a small fraction of homebound elderly in Taiwan use home-based traditional Chinese medicine, with higher use seen among patients with neurodegenerative diseases including Parkinson’s, but with notable social disparities in access and utilization.  
*Citation: Utilization of home-based traditional Chinese medicine in a homebound population under the integrated home-based medical care program in Taiwan, Journal of the Formosan Medical Association, 07/17/2025, PMID: [40681430](https://www.ncbi.nlm.nih.gov/pubmed/40681430)*

**Identifying individuals at-risk of developing Parkinson's disease using a population-based recruitment strategy: The Healthy Brain Ageing Kassel Study.**  
A stepwise, population-based screening identifies individuals at high risk of developing Parkinson’s disease based on prodromal markers, enabling the early recruitment of prodromal cohorts for future studies and preventive interventions.  
*Citation: Identifying individuals at-risk of developing Parkinson's disease using a population-based recruitment strategy: The Healthy Brain Ageing Kassel Study, NPJ Parkinson's disease, 07/18/2025, PMID: [40681552](https://www.ncbi.nlm.nih.gov/pubmed/40681552)*

---

## Basic Science Research

**Activated TBK1 promotes ACSL1-mediated microglia lipid droplet accumulation and neuroinflammation in Parkinson's disease.**  
No abstract available for summarization.  
*Citation: Activated TBK1 promotes ACSL1-mediated microglia lipid droplet accumulation and neuroinflammation in Parkinson's disease, Journal of neuroinflammation, 07/19/2025, PMID: [40684214](https://www.ncbi.nlm.nih.gov/pubmed/40684214)*

**Sex differences distinguish performance in four object recognition-based memory tasks in the Pink1-/- rat model of Parkinson's disease.**  
Pink1-/- rat models demonstrate sex differences in the onset and progression of cognitive and memory deficits, with males showing earlier impairment, offering insight into sex-specific vulnerabilities in Parkinson’s disease.  
*Citation: Sex differences distinguish performance in four object recognition-based memory tasks in the Pink1-/- rat model of Parkinson's disease, Physiology & behavior, 07/17/2025, PMID: [40683615](https://www.ncbi.nlm.nih.gov/pubmed/40683615)*

**Pharmacodynamics, safety pharmacology and local tolerance of rotigotine behenate extended-release microspheres.**  
Extended-release rotigotine behenate microspheres offer sustained therapeutic levels and a favorable preclinical safety profile, supporting further development as a monthly injectable for continuous dopaminergic stimulation in Parkinson’s disease.  
*Citation: Pharmacodynamics, safety pharmacology and local tolerance of rotigotine behenate extended-release microspheres, Toxicology and applied pharmacology, 07/17/2025, PMID: [40683571](https://www.ncbi.nlm.nih.gov/pubmed/40683571)*

**Secretory autophagy mediates lysosomal and autophagic degradation for α-synuclein proteostasis.**  
Disruptions to autophagic secretion pathways impair α-synuclein clearance and lysosomal function, implicating both secretory and degradative autophagy in maintaining proteostasis and highlighting new therapeutic avenues for Parkinson’s disease.  
*Citation: Secretory autophagy mediates lysosomal and autophagic degradation for α-synuclein proteostasis, The Journal of biological chemistry, 07/17/2025, PMID: [40683447](https://www.ncbi.nlm.nih.gov/pubmed/40683447)*

**The novel GLP-1 / GIP dual agonist DA3-CH is more effective than liraglutide in the MPTP mouse model of Parkinson's disease.**  
In a Parkinson’s mouse model, the dual GLP-1/GIP agonist DA3-CH provided stronger neuroprotection than the GLP-1 agonist liraglutide, by activating Wnt/β-catenin signaling and reducing α-synuclein accumulation.  
*Citation: The novel GLP-1 / GIP dual agonist DA3-CH is more effective than liraglutide in the MPTP mouse model of Parkinson's disease, European journal of pharmacology, 07/17/2025, PMID: [40683437](https://www.ncbi.nlm.nih.gov/pubmed/40683437)*

**mTOR-Mediated Protection Against Atrazine-Induced Ferroptosis and Dopaminergic Neurodegeneration in Parkinson's Disease Models.**  
This study shows that mTOR activation protects against atrazine-induced ferroptosis in dopaminergic neurons through the GPX4 pathway, suggesting ferroptosis and mTOR signaling as therapeutic targets for Parkinson’s disease.  
*Citation: mTOR-Mediated Protection Against Atrazine-Induced Ferroptosis and Dopaminergic Neurodegeneration in Parkinson's Disease Models, Molecular neurobiology, 07/19/2025, PMID: [40681827](https://www.ncbi.nlm.nih.gov/pubmed/40681827)*

**Peripheral Blood Mononuclear Cell Mitochondrial Bioenergetics Is Impaired in De Novo Parkinson's Disease.**  
Early, untreated Parkinson’s disease patients exhibited impaired mitochondrial bioenergetics in peripheral blood mononuclear cells, supporting this parameter as a potential early biomarker of disease and progression.  
*Citation: Peripheral Blood Mononuclear Cell Mitochondrial Bioenergetics Is Impaired in De Novo Parkinson's Disease, Molecular neurobiology, 07/18/2025, PMID: [40681825](https://www.ncbi.nlm.nih.gov/pubmed/40681825)*

**Synaptic enrichment of pSer129 alpha-synuclein correlates with dopaminergic denervation in early-stage Parkinson's disease.**  
Phosphorylated α-synuclein accumulates in dopaminergic synapses early in Parkinson’s disease, correlating with dopaminergic terminal loss and potentially contributing to the spread of Lewy body pathology.  
*Citation: Synaptic enrichment of pSer129 alpha-synuclein correlates with dopaminergic denervation in early-stage Parkinson's disease, Nature communications, 07/18/2025, PMID: [40681493](https://www.ncbi.nlm.nih.gov/pubmed/40681493)*

**YOD1 regulates oxidative damage of dopamine neurons in Parkinson's disease by deubiquitinating PKM2.**  
YOD1 is upregulated in Parkinson’s disease models, promotes oxidative stress by deubiquitinating PKM2, and its knockout improves motor deficits and reduces neuronal injury, implicating YOD1 as a novel antioxidant therapeutic target.  
*Citation: YOD1 regulates oxidative damage of dopamine neurons in Parkinson's disease by deubiquitinating PKM2, Clinical and translational medicine, 07/01/2025, PMID: [40681475](https://www.ncbi.nlm.nih.gov/pubmed/40681475)*

---

## Meta-analyses and Systematic Reviews

**The relationship between increased levels of microbiota-derived lipopolysaccharide in obesity and the pathophysiology of neurodegenerative diseases.**  
This review links elevated gut-derived lipopolysaccharide in obesity to increased systemic and neuroinflammation, protein misfolding, and neurological dysfunction, highlighting therapeutic prospects for modulating gut microbiota in Parkinson’s and related disorders.  
*Citation: The relationship between increased levels of microbiota-derived lipopolysaccharide in obesity and the pathophysiology of neurodegenerative diseases, Microbial pathogenesis, 07/17/2025, PMID: [40683546](https://www.ncbi.nlm.nih.gov/pubmed/40683546)*

**Decoding the Dialogue: Immunity and central nervous system interactions in neurodegenerative diseases.**  
This review examines the complex interplay between central and peripheral immunity in the brain, noting how neuroinflammation and immune dysregulation contribute to the pathogenesis of Parkinson’s and related neurodegenerative diseases.  
*Citation: Decoding the Dialogue: Immunity and central nervous system interactions in neurodegenerative diseases, The Egyptian journal of immunology, 07/01/2025, PMID: [40682794](https://www.ncbi.nlm.nih.gov/pubmed/40682794)*

**Metabolic Dysregulation in Parkinson's Disease: Non-Oxidative Phosphorylation and Its Role in Brain Energy Metabolism.**  
Alterations in non-oxidative phosphorylation pathways serve as both adaptive and pathogenic responses to mitochondrial dysfunction in Parkinson’s disease, underscoring the potential of metabolic imaging as a biomarker and the need for personalized therapies.  
*Citation: Metabolic Dysregulation in Parkinson's Disease: Non-Oxidative Phosphorylation and Its Role in Brain Energy Metabolism, Aging and disease, 07/06/2025, PMID: [40681352](https://www.ncbi.nlm.nih.gov/pubmed/40681352)*

---

## Narrative Reviews

**Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies.**  
Advances in biomarker frameworks are reshaping the diagnosis of dementia with Lewy bodies and Parkinson’s, with debates on the unification of disease definitions and opportunities for improved clinical trials and care.  
*Citation: Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies, Alzheimer's & dementia, 07/01/2025, PMID: [40684248](https://www.ncbi.nlm.nih.gov/pubmed/40684248)*

**α-synuclein biomarker assays: bridging research and patient care.**  
Emerging α-synuclein assays hold promise for improving early and differential diagnosis of Parkinson’s and related synucleinopathies, but current biomarkers require refinement and longitudinal validation before routine clinical use.  
*Citation: α-synuclein biomarker assays: bridging research and patient care, The Lancet. Neurology, 08/01/2025, PMID: [40683277](https://www.ncbi.nlm.nih.gov/pubmed/40683277)*

**An appraisal at a glance of metallome and disease biomarkers.**  
This review discusses the roles of metals and metalloids as disease biomarkers, covering recent analytical chemistry trends and multiomics approaches relevant for neurodegenerative diseases including Parkinson’s.  
*Citation: An appraisal at a glance of metallome and disease biomarkers, European journal of medicinal chemistry, 07/03/2025, PMID: [40683147](https://www.ncbi.nlm.nih.gov/pubmed/40683147)*

**Unveiling the Molecular Pathogenesis of MCPH: Insights From Drosophila Model System.**  
Drosophila models are valuable for dissecting molecular mechanisms underlying primary microcephaly and related neurodegenerative diseases, including Parkinson’s, due to genetic similarity and experimental versatility.  
*Citation: Unveiling the Molecular Pathogenesis of MCPH: Insights From Drosophila Model System, Development, growth & differentiation, 07/19/2025, PMID: [40682423](https://www.ncbi.nlm.nih.gov/pubmed/40682423)*

**Opportunities and challenges for deep brain stimulation electrode-guided neurofeedback for symptom mitigation in neurological and psychiatric disorders.**  
DBS electrode-guided neurofeedback is an emerging neuromodulation approach with potential to improve symptoms in Parkinson’s and other neurological disorders, though further research is needed for clinical translation.  
*Citation: Opportunities and challenges for deep brain stimulation electrode-guided neurofeedback for symptom mitigation in neurological and psychiatric disorders, Journal of neuroengineering and rehabilitation, 07/18/2025, PMID: [40682108](https://www.ncbi.nlm.nih.gov/pubmed/40682108)*

**Focused ultrasound therapy for movement disorders.**  
MR-guided focused ultrasound offers a minimally invasive treatment for movement disorders like Parkinson’s, with proven safety and efficacy in trials and expanding possibilities for neurodegenerative disease care.  
*Citation: Focused ultrasound therapy for movement disorders, The Lancet. Neurology, 08/01/2025, PMID: [40683278](https://www.ncbi.nlm.nih.gov/pubmed/40683278)*

**Accelerating the path towards a cure for Parkinson's disease.**  
No abstract available for summarization.  
*Citation: Accelerating the path towards a cure for Parkinson's disease, The Lancet. Neurology, 08/01/2025, PMID: [40683258](https://www.ncbi.nlm.nih.gov/pubmed/40683258)*

---

## Case Reports & Case Series

No papers in this category.

---

## Other

**Decision tree for severity assessment of neurodegenerative diseases using possibility approach and gait dynamics.**  
A novel decision tree-based computer-aided framework using normalized gait features accurately assesses disease type and severity across Parkinson’s, ALS, and Huntington’s, offering a promising objective tool for clinical management.  
*Citation: Decision tree for severity assessment of neurodegenerative diseases using possibility approach and gait dynamics, Scientific reports, 07/19/2025, PMID: [40683959](https://www.ncbi.nlm.nih.gov/pubmed/40683959)*

---